Codexis makes a promotion

David Anton becomes cto and takes new role of senior vp, process development and manufacturing

US biotechnology firm Codexis, based in Redwod, California, has promoted David Anton to chief technology officer and senior vice president of process development and manufacturing, a new position. He will continue to report to Alan Shaw, president and chief executive.

Anton joined Codexis in 2008 after a 25-year career with DuPont. He was vice president, research and development for Codexis Bioindustrials from 2008–09, and senior vice president, research and development from 2009–11.

‘Under Dave Anton's leadership, Codexis r&d has grown to an organisation that today is developing commercial products and processes in four global markets – biofuels, pharmaceuticals, carbon capture and biobased chemicals,’ said Shaw. ‘His experience in technology development and commercialisation – including commercial scale-up and manufacturing – will be important as we continue our transition to a product company.’

Codexis develops optimised biocatalysts that make industrial processes faster, cleaner and more efficient.

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients

Global partnership to expand pharma biocatalysis uptake

Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. Dr Kevin Robinson caught up with Porton’s Oliver Ju and Codexis’ John Nicols to find our more
Pharmaceutical

Riding the wave of protein revolution

Optimised biocatalysts for the pharmaceutical and food industries
Manufacturing

Porton Pharma Solutions and Codexis launch global partnership

The partnership reinforces the benefits of reduced costs, enhanced sustainability and improved product quality that biocatalysts can deliver to the manufacturing of the world's small molecule pharmaceuticals
Ingredients

Codexis to exhibit at CPhI Worldwide 2017

Codexis is leading the way with powerful biocatalysts that integrate biology and chemistry
Ingredients

Codexis reports loss of US$7m in Q1

Revenue increased by 18% to $8m after significant growth in core biocatalyst R&D revenues and product sales
Manufacturing

Codexis reports 2015 fourth quarter and full year financial results

Financial outlook for 2016 is for another year of growth with revenues in the range of US$46–49m
Subscribe now